Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

8.91
+0.855010.61%
Post-market: 9.010.0970+1.09%19:30 EDT
Volume:1.76M
Turnover:15.33M
Market Cap:588.18M
PE:-2.37
High:8.99
Open:8.14
Low:8.13
Close:8.06
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.96
T/O Rate:3.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:8.20
PE(LYR):-2.37

Loading ...

Regenxbio Shares up 11.2% Premarket After Report US FDA to Reverse Rejection of Co's Rare-Disease Drug

THOMSON REUTERS
·
Jun 22

Regenxbio up 25% after saying FDA will reverse rejection, consider application

TIPRANKS
·
Jun 22

BRIEF-FDA Will Reverse Rejection Of Third Rare-Disease Drug, Regenxbio Says- WSJ

Reuters
·
Jun 22

Regenxbio tells WSJ that FDA will reverse rejection of drug

TIPRANKS
·
Jun 22

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

MT Newswires Live
·
Jun 18

REGENXBIO Up Over 23%, on Pace for Largest Percent Increase Since September 2021 -- Data Talk

Dow Jones
·
Jun 18

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)

TIPRANKS
·
Jun 06

REGENXBIO Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 06

Regenxbio price target lowered to $26 from $30 at H.C. Wainwright

TIPRANKS
·
Jun 06

Regenxbio Inc. : H.c. Wainwright Cuts Target Price to $26 From $30

THOMSON REUTERS
·
Jun 06

Regenxbio shareholders approved non-executive stock option exchange program at annual meeting

Reuters
·
Jun 03

Stifel Nicolaus Sticks to Their Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
May 27

Nippon Shinyaku posts FY2025 earnings call transcript

Reuters
·
May 25

Regenxbio joins RBC Global Healthcare Conference fireside chat

Reuters
·
May 19

Regenxbio price target lowered to $16 from $17 at Morgan Stanley

TIPRANKS
·
May 15

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says

MT Newswires Live
·
May 15

REGENXBIO Is Maintained at Overweight by Barclays

Dow Jones
·
May 15

Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
May 15

Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)

TIPRANKS
·
May 15

Regenxbio Inc : Bofa Global Research Cuts Price Objective to $14 From $25

THOMSON REUTERS
·
May 15